We are focused on developing and commercializing drugs that treat very serious lung infections in orphan disease populations.
Investment Thesis
Our lead product candidate, ARIKACE, has multiple clinical and patient benefits.
We have two near-term commercial opportunities in orphan lung diseases.
We have near-term value-driving milestones.
We have a solid and broad IP portfolio.
We are well-capitalized and are building out our infrastructure.
May 14, 2013
Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe
May 13, 2013
Insmed to Present at the UBS Global Healthcare Conference
May 20, 2013
Insmed to Present at the UBS Global Healthcare Conference
Listen to webcast
May 16, 2013
Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Listen to webcast
Insmed actively publishes and presents clinical data for ARIKACE.
Want to stay up to date on our news, events, and filings?
Set up your email alerts. Learn More